| gTLD | Full Legal Name | E-mail suffix | Detail | | .cancerresearch | Australian Cancer Research Foundation | acrf.com.au | View |
INTRODUCTION
All domain name registrations in the .cancerresearch TLD will be registered to and maintained by ACRF for its own exclusive use. ACRF will not distribute or transfer control or use of any registrations in the .cancerresearch TLD to any third party that is not an Affiliate, as that term is defined in clause 2.9(c) of the Registry Agreement. As such, ACRF will maintain complete control over .cancerresearch domain name registrations, as facilitated by the imposition of eligibility restrictions and internal policies and processes. ACRF has interpreted this question broadly and prepared this response taking into consideration social costs and other negative consequences facing consumers and Internet users who will access content through the .cancerresearch TLD; likewise, these are considered eliminated or minimised by the manner in which ACRF will operate the .cancerresearch TLD.
METHOD OF RESOLVING MULTIPLE APPLICATIONS
Multiple applications are not anticipated in the .cancerresearch TLD, as domain name registrations will be for controlled by ACRF for its exclusive use in the interests of the ACRF brand. Registrations will not be made commercially available and eligibility to register domain names will be limited to specifically authorised individuals under ACRF’s control. Thus, there are no competing interests and or opportunities for competing applications to be made. The decision-making authority as to which domain names will be registered and for which purposes will be not vested in a single individual; this will be addressed through internal processes regarding domain name registration, requiring approvals within established reporting lines and the use of usernames and passwords to register domain names. Compliance with these processes will ensure that multiple applications for the same name are not made.
COST BENEFITS TO REGISTRANTS
Registrations will not be commercially available in the .cancerresearch TLD; cost benefits to registrants are therefore not applicable to the TLD.
CONTRACTUAL COMMITMENTS TO REGISTRANTS
Registrations will not be commercially available in the .cancerresearch TLD; contractual commitments regarding price escalation are therefore also not applicable to the TLD.
OTHER OPERATING RULES WHICH ELIMINATE OR MINIMISE SOCIAL COSTS
By imposing strict eligibility restrictions and internal processes regarding domain name registration and restricting the .cancerresearch TLD to uses that clearly support its mission⁄purpose and thus the ACRF business, it is anticipated that vulnerabilities to the registrant and the Internet public who access content through the .cancerresearch TLD can be eliminated. This will be safeguarded through internal policies and procedures which ensure that registrations are made by authorised representatives of ACRF using established reporting lines. Further, abusive registrations and use of registrations will be prevented by having in place and enforcing a robust anti-abuse policy; this policy is described in detail in the response to Question 28.
| gTLD | Full Legal Name | E-mail suffix | Detail | | .ansons | CBM Creative Brands Marken GmbH | ansons.de | View |
INTRODUCTION
The applicant of the .ansons TLD is Creative Brands Marken GmbH (referred to throughout this answer as ‘CBM’).
All domain name registrations in the .ansons TLD are planned to be registered to and maintained by CBM for its own exclusive use. CBM will not distribute or transfer control or use of any registrations in the .ansons TLD to any third party that is not an Affiliate, as that term is defined in clause 2.9(c) of the Registry Agreement. As such, CBM will maintain complete control over .ansons domain names, as facilitated by the imposition of eligibility restrictions enforced through internal policies and processes.
CBM has interpreted this question broadly and prepared this response taking into consideration social costs and other negative consequences facing consumers and Internet users who will access content through the .ansons TLD; these are likewise considered eliminated or minimised by the manner in which CBM will operate the .ansons TLD.
METHOD OF RESOLVING MULTIPLE APPLICATIONS
Multiple applications are not anticipated in the .ansons TLD, as domain name registrations will be for controlled by CBM for its exclusive use in the interests of the Anson’s brand. Registrations will not be made commercially available and eligibility to register domain names will be limited to specifically authorised individuals under CBM’s control. Thus, there are no competing interests or opportunities for competing applications to be made. The decision-making authority as to which domain names will be registered will be centralised and internal processes will be in place regarding domain name registration, requiring approvals within established reporting lines and the use of usernames and passwords to register domain names. Compliance with these processes will ensure that multiple applications for the same name are not made.
COST BENEFITS TO REGISTRANTS
Registrations will not be commercially available in the .ansons TLD; cost benefits to registrants are therefore not applicable to the TLD.
CONTRACTUAL COMMITMENTS TO REGISTRANTS
Registrations will not be commercially available in the .ansons TLD; contractual commitments regarding price escalation are therefore also not applicable to the TLD.
OTHER OPERATING RULES WHICH ELIMINATE OR MINIMISE SOCIAL COSTS
By imposing strict eligibility restrictions and restricting the .ansons TLD to uses that clearly support its mission⁄purpose and thus the Anson’s brand and business, it is anticipated that vulnerabilities to the registrant and users can be eliminated. This will be safeguarded through internal policies and procedures which ensure that registrations are made by authorised employees within established reporting lines. Further, abusive registrations and use of registrations will be prevented by having in place and enforcing a robust anti-abuse policy; this policy is described in detail in the response to Question 28